Grigorios Rombopoulos

Grigorios Rombopoulos

Auto-generated profile, based on publicly available information

Grigorios Rombopoulos

A Novartis Hellas SACI , Athens , Greece

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2013 in Hormones
Verified
Journal Article
Closed access
GRGrigorios Rombopoulos
Grigorios Rombopoulos
MHMagdalini Hatzikou
Magdalini Hatzikou
DLDimitra Latsou
Dimitra Latsou
IYIoannis John Yfantopoulos
Ioannis John Yfantopoulos
To estimate the impact of hypoglycemia on the Quality of Life (QoL) and its prevalence in patients with type 2 diabetes mellitus (T2DM) in Greece. A cross-sectional epidemiological study was conducted in 6631 patients with T2DM. QoL was assessed with the patient self-administered ADDQoL-19. Reliability analysis of patients' outcomes was performed to assess internal consistency of the ADDQoL-19. Patients were categorized according to hypoglycemia experience and diabetes control. Controlled patients were considered as having Hb1Ac 7% (53 mmol/mol) and 20.4% of patients had a history of laboratory-confirmed hypoglycemia. The mean age was 60 years and the mean T2DM duration was 10 years. The mean QoL score was -3.09±1.9 for the total sample and the mean score of non-hypoglycemic patients was -3.05±2, while the respective score of hypoglycemic patients was -3.26 ±1.8, (p≤0.001). Similar results were observed in the group of controlled and uncontrolled patients, who scored -2.73±1.7 and -3.33±1.9, respectively (p≤0.001). Comparable results were identified in the majority of the ADDQoL-19 instrument dimensions. The QoL of T2DM patients is affected significantly by hypoglycemia and the level of disease control. In diabetes treatment, the ultimate goal should be optimal glycemic control without debilitating hypoglycemic episodes which compromise patients' QoL.

19 May 2015 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
GRGrigorios Rombopoulos
Grigorios Rombopoulos
MHMagdalini Hatzikou
Magdalini Hatzikou
AAAthanasios Athanasiadis
Athanasios Athanasiadis
MEMoyses Elisaf
Moyses Elisaf
Objective. To evaluate the differences in treatment compliance with vildagliptin/metformin fixed-dose versus free-dose combination therapy in patients with type 2 diabetes mellitus (T2DM) in Greece.Design. Adult patients with T2DM, inadequately controlled with metformin monotherapy, (850 mg bid), participated in this 24-week, multicenter, observational study. Patients were enrolled in two cohorts: vildagliptin/metformin fixed-dose combination (group A) and vildagliptin metformin free-dose combination (group B).Results. 659 patients were enrolled, 360 were male, with mean BMI 30.1, mean T2DM duration 59.6 months, and mean HbA1c at baseline 8%; 366 patients were assigned to group A and 293 to group B; data for 3 patients was missing. In group A, 98.9% of patients were compliant with their treatment compared to 84.6% of group B. The odds ratio for compliance in group A versus B was (OR) 18.9 (95% CI: 6.2, 57.7;P<0.001). In group A mean HbA1c decreased from 8.1% at baseline to 6.9% (P<0.001) at the study end and from 7.9% to 6.8% (P<0.001) in group B.Conclusions. Patients in group A were more compliant than patients in group B. These results are in accordance with international literature suggesting that fixed-dose combination therapies lead to increased compliance to treatment.

21 May 2015 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
IMIlias Migdalis
Ilias Migdalis
GRGrigorios Rombopoulos
Grigorios Rombopoulos
MHMagdalini Hatzikou
Magdalini Hatzikou
CMChristos Manes
Christos Manes
NKNikolaos Kypraios
Nikolaos Kypraios
NTNikolaos Tentolouris
Nikolaos Tentolouris
Objective.This study aimed to estimate the mean annual cost of treating type 2 diabetes mellitus patients (T2DM) including complications and comorbidities in Greece.Design.A noninterventional retrospective study was based on patient level data analysis (bottom-up approach) from medical records, with at least 10-year-follow-up data.Results.The total annual cost per patient for managing diabetes in Greece was estimated at € 7,111 and was, statistically significantly, higher for patients with inadequate glycemic control (Hba1c>7%) versus patients with adequate control (Hba1c=7%) (€ 7,783 versus € 6,366, resp.; P=0.017). This was mainly attributed to difference in CV hospitalizations between groups 14/111 versus 4/100, respectively,OR=3.46(95% CI: 1.10–10.9) for inadequately controlled patients. The largest component of cost was management of comorbidities, accounting for 48% of costs, and pharmaceutical treatment at 35.9% while only 14.9% was attributed to diabetes treatment per se. Obese men and patients with poor education are the groups with higher treatment costs.Conclusions.This is the first study to capture all cost components and the real burden of diabetes in Greece. Comorbidities were found to account for almost half of total cost, significantly higher in nonoptimally controlled diabetes patients.

1 March 2007 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
NANicholaos George Angelopoulos
Nicholaos George Angelopoulos
GPG. Papanikolaou
G. Papanikolaou
MNMarina Noutsou
Marina Noutsou
GRG. Rombopoulos
G. Rombopoulos
AGA. Goula
A. Goula
GTG. Tolis
G. Tolis
Among specific diabetes subtypes secondary to pancreatopathies, hereditary hemochromatosis is an inherited disorder of iron metabolism resulting in excessive iron overload and tissue damage in various organs. We here report the case of a man with the young-onset form of the disease and describe his glycaemic status before and during venesection therapy. A 25-year old man visited our clinic in Athens, Greece, with hypogonadotropic hypogonadism due to hereditary hemochromatosis. Genetic analysis revealed that he was suffering from the juvenile aggressive form and treatment was initiated with frequent phlebotomies in conjunction with androgen substitution. Within 18 months of therapy ferritin level was normalized and hypogonadism was fully restored. Despite severe iron overload, glucose tolerance remained normal during the vari-ous stages of the disease, although alterations in both insulin secretion and sensitivity were detected. Present data indicate that in juvenile hemochromatosis, the efficacy of the chelation therapy and probably the chronic interval required to restore normal iron concentration both play important roles in the formation of glucose metabolism characteristics.

9 March 2016 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
GRGrigorios Rombopoulos
Grigorios Rombopoulos
EPElena Panitti
Elena Panitti
CVChristos Varounis
Christos Varounis
CKChristos Katsinas
Christos Katsinas
ISIoannis Stefanidis
Ioannis Stefanidis
DGDimitrios Goumenos
Dimitrios Goumenos
Objective: Management of patients with type 2 diabetes (T2DM) and stage 3 to 5 chronic kidney disease (CKD) is challenging. The aim of the ‘LEARN’ study was to depict treatment patterns employed in this population and to record comorbidities, glycemic control and hypoglycemia episodes in the routine clinical practice in Greece.Research design and methods: ‘LEARN’ was a non-interventional, multicenter, cross-sectional study conducted in Greece between 15-February-2013 and 04-July-2013. A total of 120 adult patients were enrolled from four hospital sites in different geographic regions of Greece.Results: Participants had a mean age of 69.1±10.3 years and a male: female ratio of 2:1. Nearly all patients (99.2%) suffered from at least one comorbidity, with hypertension (95.8%) and hyperlipidemia/dyslipidemia (78.3%) being the most prevalent. Of the overall study population, 57.5% was managed with insulin therapy only, 30.8% with oral antidiabetics only and 11.7% with a combination of insulin and oral ...